PHOENIX, AZ / ACCESSWIRE / November 14, 2018 / Pressure BioSciences Inc. (OTCQB: PBIO) (the "Company") is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry. The Company's President and CEO, Richard T. Schumacher, joined Stock Day's Everett Jolly to discuss a new addition to the PBI Team, their proprietary Ultra Shear Technology ("UST") platform, and their potential game-changing entre into the CBD Oil market.
As the interview began, Mr. Jolly asked Mr. Schumacher about the announcement of Dr. Brad Young joining the company as Senior Vice President and Chief Commercial Operator. Mr. Schumacher explained that Dr. Young is a very accomplished scientist and businessman. He said Dr. Young earned a Ph.D. in biochemistry from the University of Maryland School of Medicine and an MBA from UC Berkeley.
Mr. Schumacher commented: "He is quite a fellow. I've known him personally for 6 years, and our Chairmen Jeff has known him for twice that time. We've talked with him in social and professional settings a lot over the years, and when he mentioned that he had decided to move back to the east coast from San Francisco earlier this year, Jeff and I both said "here's an opportunity. He combines the acumen, skills, and experience of a guy who has had both an entrepreneurial as well as a big company past."
Mr. Schumacher continued: "He's running the PBI commercial program, including business development. He will be working with many of the companies that we believe should be and could be offering our sample preparation instrumentation in a package along with their own analytical instrumentation. We think this type of collaboration will let one plus one equal three. Our instruments are used to break apart samples to get them ready to be tested, while the other companies have the analytical equipment that will be used to test the samples. It makes sense to put our instruments together with theirs."
Mr. Jolly then stated that the company had recently announced it had achieved a milestone in their Ultra Shear Technology Program. He asked Mr. Schumacher for an explanation of UST and asked about PBI's planned market penetration. Mr. Schumacher explained that PBIO's Ultra Shear Technology is one of their three patented technology platforms. The others are Pressure Cycling Technology ("PCT") and the PreEMT platform they recently purchased from BaroFold Corporation. Mr. Schumacher stated that PBI has over 300 PCT instruments in the field worldwide, mainly for biomarker discovery and biopharma drug development and QC. He also stated that the PreEMT technology platform is used to impact and improve the quality of protein therapeutics, primarily through high-pressure protein refolding.
Mr. Schumacher commented: "We use high pressure to solve problems. There are a number of applications in many exciting industries, like the food industry, where high pressure is now being used to solve problems and to make products better. A number of food items that we eat are put under intense pressure to kill bacteria that cause disease. By using pressure, the manufacturer does not need to add chemicals to kill or reduce the amount of disease-causing bacteria. As mentioned, we have two technology platforms based on high pressure. PBI's brilliant engineers and scientists were innovative enough to combine ultra-high pressure with shearing. Shearing is cutting. The combination of ultra high pressure and shearing, with just a quick controlled burst of heat, became our newest technology platform, Ultra Shear Technology".
Mr. Schumacher continued: "We believe that UST will be incredibly important in markets that can use nanoemulsions. As we know, oil and water do not generally mix. However, if you break oil drops down to tiny, sub-microscopic, nano droplets then the oil will actually dissolve in water. So that is what UST does and does well – it shears oil into nano droplets to make long-term stable nanoemulsions. We believe that UST can be enormously valuable in the markets like cosmetics, pharmaceuticals, paints, and nutraceuticals.
Mr. Jolly then asked if Pressure BioSciences Inc. had started to reach out to various cannabis technology companies, like those in the CBD area. He asked if CBD was a new market that could use PBI's UST platform, or if PBI was actually looking to get into the CBD business. Mr. Schumacher clearly stated that PBI was first and foremost an instrument company. He said their existing PCT instruments, although primarily used by researchers in the life sciences area, are also used for applications in food, cosmetics, and other fields. He added that future UST instruments will most likely also be used for many different applications in a variety of fields, including the CBD industry.
Mr. Schumacher commented: "CBD comes out of the Cannabis plant in an oil. When you ingest CBD plant oil it doesn't get absorbed very well. In fact, most people in the industry believe that less than 10 percent of the CBD in that CBD Oil is actually absorbed into your body. So, you are losing a lot of the beneficial aspects of the CBD. What a lot of CBD companies are looking to do now, and what some companies have tried, is to make the CBD Oil water soluble. But how do you make an oil go into water? Well we believe we can do just that. That's what we hope to show now that we have a working prototype of the Ultra Shear instrument."
Mr. Schumacher continued: "So are we a cannabis company, no. Are we a tools company making instruments for many applications and fields, absolutely. And are we going to be able to sell the future UST system into the cannabis field, we think so."
Mr. Schumacher mentioned that PBIO has been in contact with about a dozen CBD companies that have reached out to them to discuss the potential of water soluble CBD Oil. He said that CBD companies want to be more cost effective as a manufacturer, which means they don't want to have too little or too much CBD Oil in their products. On the other hand, the consumer wants to ingest the right amount of CBD for the benefit they hope the get. Mr. Schumacher said that PBI might have the answer, as they believe that CBD Oil can be made water soluble with UST processing. This would allow manufacturers the ability to better determine the amount of CBD Oil needed for ingestion, which means their products could become more cost-effective. Mr. Jolly then remarked that UST might just be a future game-changer for the CBD industry.
Mr. Schumacher responded: "So, is UST a game changer? I think any company that comes up with a good method to make truly water soluble CBD Oil may have a game-changer."
Mr. Schumacher also said: "There are certainly ways to make CBD Oil so-called water soluble, so you have to be careful. Some are bad in that the manufacturer might use an over-abundance of emulsifiers and surfactants, or processing methods that are not the best. But there are also good ways. We believe that Ultra Shear Technology is a good way. We use science, we use physics, we use pressure. We don't have to add a lot of chemicals, we don't have to do a lot of things others might do. We believe that by using pressure and shearing through our patented valve, we can achieve what we understand the CBD market is really looking for, a good, solid, safe way to make water soluble CBD plant oil."
Mr. Jolly then ended the interview by saying he wished Mr. Schumacher and PBIO continued success.
To hear all of Mr. Schumacher's interview with Stock Day, please go here: https://upticknewswire.com/featured-interview-ceo-ric-schumacher-of-pressure-biosciences-inc-otcqb-pbio-9/
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, PBIO is actively expanding the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
For more information: https://www.pressurebiosciences.com/about-us
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company's most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.
About Uptick Newswire and the "Stock Day" Podcast:
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its "Stock Day" Podcast, which is the number one radio show of its kind in America. The Uptick Network "Stock Day" Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of "Stock Day," and Uptick Newswire encourages listeners to visit the company's message board at https://investorshangout.com/
SOURCE: Uptick Newswire
View source version on accesswire.com:
https://www.accesswire.com/528018/Pressure-BioSciences-Inc-Discusses-an-Exciting-Addition-to-Its-Management-Team-Their-Innovative-Ultra-Shear-Technology-and-How-They-Hope-to-Help-Shape-the-Rapidly-Growing-CBD-Oil-Market-on-Uptick-Newswires-Stock-Day-Podcast
